Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

脑转移（Brain Metastasis，BM）是非小细胞肺癌（Non-Small Cell Lung ...

GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in ...

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

Innovent Biologics (HKEX: 01801) has formed a strategic partnership with ASK Pharm (SZ: 002755) to commercialize limertinib, ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Indeed, additional promising drugs with multitarget activity (including ... Alternative RTK pathways that are activated following EGFR inhibition is another area for investigation.

The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.

Preliminary results for BDTX-1535 in NSCLC patients are expected in early 2025. Read more about Black Diamond Therapeutics ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the ...

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...